NCT07178613尚未招募1 期
Assessment of the Dose Safety and Efficacy of Serine Combined With Fluorouracil Drugs
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 20
- 主要终点
- Safety of Oral Serine
研究概览
简要总结
This study evaluates the dose safety and efficacy of serine in combination with fluoropyrimidine-based therapies. Primary objective: To determine the safety of oral serine administration.
Secondary objectives: 1. To assess the preliminary efficacy of serine in the study population. 2. To establish the recommended Phase 2 dose for oral serine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years (inclusive), male or female;
- •Patients with advanced colorectal cancer confirmed by histopathological or cytological examination, eligible for standard first-line treatment with fluorouracil-containing regimens.
- •Patients must have at least one measurable lesion.
- •ECOG performance status ≤
- •Expected survival ≥ 3 months;
- •Major organ functions are essentially normal, with laboratory tests meeting the following criteria:
- •Hematology (no transfusion of blood or blood products within 7 days prior to testing; no use of G-CSF or other hematopoietic growth factors for correction):
- •Absolute neutrophil count ≥1.5×10⁹/L ; Platelets ≥75×10⁹/L ; Hemoglobin ≥90 g/L;
- •Creatinine clearance (CrCl) or estimated glomerular filtration rate (eGFR) >60 mL/min/1.73 m² (Cockcroft-Gault formula);
- •Serum total bilirubin <1.5×ULN; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5×ULN or ≤5×ULN (for subjects with liver metastases); Albumin (ALB) ≥30 g/L;
- •Coagulation Function:
- •International Normalized Ratio (INR) or Prothrombin Time (PT) < 1.5×ULN. If the subject is receiving anticoagulant therapy, PT is acceptable as long as it falls within the therapeutic range for the anticoagulant drug.
- •Cardiovascular System:
- •Ejection Fraction (EF) 55%-70%; QTc Interval: Male ≤440ms; Female ≤450ms.
- •Serum pregnancy tests for female subjects of childbearing potential during the screening period must be negative. Female/male subjects with reproductive potential must be willing to use reliable contraception throughout the study period (i.e., from signing the informed consent form until 90 days after the last study drug administration), including but not limited to: abstinence, male partner having undergone vasectomy, female sterilization, effective intrauterine device (IUD), and effective contraceptive medication.
- •Patients voluntarily participate in this study, sign informed consent forms, and demonstrate good compliance.
排除标准
- •Trial Participation Restrictions: Currently participating in or having received investigational drug/device treatment within the past 4 weeks;
- •Prior Fluorouracil-Based Therapy Restrictions: History of ≥Grade 3 toxicity (e.g., myelosuppression, gastrointestinal toxicity) following prior fluorouracil-based therapy, deemed unsuitable for re-administration by the investigator;
- •Recent Surgery Restriction: Undergone major surgery (excluding diagnostic biopsy) within 28 days prior to first dosing, or scheduled for surgery during the study period;
- •Metabolic and Nutritional Status Restriction: Presence of severe malnutrition (BMI < 18.5 or serum albumin < 30 g/L), or inability to supplement serine orally (e.g., malabsorption syndrome, short bowel syndrome); Known serine metabolism disorders (e.g., PHGDH/PSAT1 gene mutation-related diseases);
- •Concurrent severe disease restrictions: Severe cardiovascular disease (NYHA Class III/IV heart failure, myocardial infarction within 6 months, uncontrolled hypertension >150/100 mmHg); severe respiratory disease (COPD, GOLD Stage ≥3, interstitial lung disease); Active infection (requiring systemic antibiotic/antiviral therapy);
- •Active HIV/viral hepatitis: HIV-positive status, or active hepatitis B (HBV-DNA ≥ 2000 IU/mL), or active hepatitis C (HCV-RNA positive); (Note: Patients with HBV-DNA < 2000 IU/mL receiving antiviral therapy may be enrolled);
- •Neurological disorders: Uncontrolled brain metastases (with intracranial hypertension or neurological symptoms), or history of severe psychiatric illness/substance abuse (impeding treatment compliance);
- •Allergy history: Known allergy to fluorouracil-based drugs or serine supplements;
- •Pregnancy/lactation: Pregnant or lactating women (patients of childbearing potential must use highly effective contraception);
- •Other conditions deemed ineligible by the investigator: Any concomitant conditions or laboratory abnormalities that may interfere with study results, increase risk, or compromise patient safety.
研究组 & 干预措施
Serine + Fluoropyrimidine Group
Other
干预措施: Serine（Oral） (Drug)
Serine + Fluoropyrimidine Group
Other
干预措施: Fluoropyrimidine Drugs (Drug)
结局指标
主要结局
Safety of Oral Serine
时间窗: Up to 28 days
Assess the safety of oral serine, including the occurrence of adverse events and dose - limiting toxicities
次要结局
未报告次要终点
研究者
相似试验
招募中
1 期
Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE)Epilepsy, Drug ResistantNCT06719791Xuanwu Hospital, Beijing15
已完成
3 期
Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in HypertensionHypertensionNCT05820880Institut de Recherches Internationales Servier532
已完成
3 期
Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.Essential HypertensionNCT05288400Servier150
Unknown
不适用
Improving the Safety of Fluoropyrimidine-based ChemotherapyNeoplasmsNCT04194957The Netherlands Cancer Institute1,440
已完成
4 期
Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving MyforticRenal TransplantationNCT00713284California Pacific Medical Center Research Institute29